Background: Apremilast is the first small molecule approved for the treatment of moderate-to-severe psoriasis in adult patients; however, real-life data are still limited. We investigated the effectiveness and safety of this drug in a multicentre real-world setting. Methods: We retrospectively reviewed data from all psoriatic patients who received at least one dose of apremilast, collecting demographic data and medical history, at baseline and periodically until 36 months. Results: A total of 111 patients entered in the study. The mean drug survival duration was 21.8±10.6 months, significantly shorter when comorbidities were≥3 and if biologic drugs were previously administered.ΔPASI90 was achieved in 29% of patients and ΔPASI50 in 68% at T4;the rate of ΔPASI improvement increased progressively at T12, T24, T36 in patients who continued to receive apremilast.At the end of the study 50 patients discontinued the treatment because of adverse events (19.8%), primary failure(19%) or secondary failure(6.3%). Conclusions: Apremilast proved to be an effective, safe, and manageable drug, showing effectiveness also in difficult-to-treat patients with psoriasis, with a favourable tolerability profile and a potentially valid weight loss effect. We believe that treating patients with few comorbidities who are naive to biological therapy may result in higher response rates and longer mean drug survival.

Use of apremilast in the psoriasis treatment: a real-life multicentre Italian experience / Filippi, Federica; Patrizi, Annalisa; Iezzi, Luca; Carpanese, Miriam A; Conti, Andrea; Lasagni, Claudia; Tabanelli, Michela; D'Adamio, Simone; DI Nuzzo, Sergio; Cortelazzi, Chiara; DI Lernia, Vito; Peccerillo, Francesca; Corazza, Monica; Odorici, Giulia; Bardazzi, Federico. - In: ITALIAN JOURNAL OF DERMATOLOGY AND VENEREOLOGY. - ISSN 2784-8450. - (2021). [10.23736/S2784-8671.21.07125-5]

Use of apremilast in the psoriasis treatment: a real-life multicentre Italian experience

DI Nuzzo, Sergio;Cortelazzi, Chiara;
2021

Abstract

Background: Apremilast is the first small molecule approved for the treatment of moderate-to-severe psoriasis in adult patients; however, real-life data are still limited. We investigated the effectiveness and safety of this drug in a multicentre real-world setting. Methods: We retrospectively reviewed data from all psoriatic patients who received at least one dose of apremilast, collecting demographic data and medical history, at baseline and periodically until 36 months. Results: A total of 111 patients entered in the study. The mean drug survival duration was 21.8±10.6 months, significantly shorter when comorbidities were≥3 and if biologic drugs were previously administered.ΔPASI90 was achieved in 29% of patients and ΔPASI50 in 68% at T4;the rate of ΔPASI improvement increased progressively at T12, T24, T36 in patients who continued to receive apremilast.At the end of the study 50 patients discontinued the treatment because of adverse events (19.8%), primary failure(19%) or secondary failure(6.3%). Conclusions: Apremilast proved to be an effective, safe, and manageable drug, showing effectiveness also in difficult-to-treat patients with psoriasis, with a favourable tolerability profile and a potentially valid weight loss effect. We believe that treating patients with few comorbidities who are naive to biological therapy may result in higher response rates and longer mean drug survival.
Use of apremilast in the psoriasis treatment: a real-life multicentre Italian experience / Filippi, Federica; Patrizi, Annalisa; Iezzi, Luca; Carpanese, Miriam A; Conti, Andrea; Lasagni, Claudia; Tabanelli, Michela; D'Adamio, Simone; DI Nuzzo, Sergio; Cortelazzi, Chiara; DI Lernia, Vito; Peccerillo, Francesca; Corazza, Monica; Odorici, Giulia; Bardazzi, Federico. - In: ITALIAN JOURNAL OF DERMATOLOGY AND VENEREOLOGY. - ISSN 2784-8450. - (2021). [10.23736/S2784-8671.21.07125-5]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2903401
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact